ABBV

NYSE

AbbVie Inc.

Healthcare

Drug Manufacturers - General

United States

257.12USD

+2.12 (+0.83%)

Market Cap: 450.61B USD

Revenue and Net Income

Values in USD

Income Statement

Values in USD

Financial item	TTMJun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Total Revenue	64.39B	61.16B	56.33B	54.32B	58.05B
Cost of Revenue	18.36B	18.20B	16.90B	20.41B	17.41B
Gross Profit	46.02B	42.96B	39.43B	33.90B	40.64B
Operating Expense	24.17B	22.86B	27.54B	20.37B	21.83B
Operating Income	21.85B	20.09B	11.89B	13.54B	18.81B
Net Non Operating Interest Income Expense	-2.65B	-2.63B	-2.16B	-1.68B	-2.04B
Other Income Expense	-10.51B	-10.87B	-6.02B	-5.60B	-3.29B
Pretax Income	8.70B	6.60B	3.72B	6.25B	13.48B
Tax Provision	2.38B	2.36B	-570.00M	1.38B	1.63B
Net Income Common Stockholders	6.27B	4.19B	4.24B	4.82B	11.78B
Diluted NI Available to Com Stockholders	6.27B	4.19B	4.24B	4.82B	11.78B
Basic EPS	3.54	2.37	2.42	2.75	6.69
Diluted EPS	3.54	2.37	2.39	2.72	6.63
Basic Average Shares	1.77B	1.77B	1.77B	1.77B	1.77B
Diluted Average Shares	1.77B	1.77B	1.77B	1.77B	1.78B
Total Operating Income as Reported	16.87B	15.07B	9.14B	12.76B	18.12B
Total Expenses	42.54B	41.07B	44.44B	40.78B	39.24B
Net Income from Continuing & Discontinued Operation	6.31B	4.23B	4.28B	4.86B	11.84B
Normalized Income	9.97B	7.48B	6.47B	5.58B	12.58B
Interest Income	270.00M	266.00M	648.00M	540.00M	186.00M
Interest Expense	2.92B	2.89B	2.81B	2.22B	2.23B
Net Interest Income	-2.65B	-2.63B	-2.16B	-1.68B	-2.04B
EBIT	11.62B	9.49B	6.52B	8.47B	15.71B
EBITDA	19.48B	17.63B	14.91B	17.17B	24.17B
Reconciled Cost of Revenue	18.36B	18.20B	16.90B	20.41B	17.41B
Reconciled Depreciation	7.87B	8.14B	8.39B	8.70B	8.47B
Net Income from Continuing Operation Net Minority Interest	6.31B	4.23B	4.28B	4.86B	11.84B
Total Unusual Items Excluding Goodwill	-5.04B	-5.07B	-2.78B	-924.00M	-845.00M
Total Unusual Items	-5.04B	-5.07B	-2.78B	-924.00M	-845.00M
Normalized EBITDA	24.52B	22.70B	17.69B	18.10B	25.02B
Tax Rate for Calcs	0.27	0.36	0.21	0.22	0.12
Tax Effect of Unusual Items	-1.38B	-1.82B	-583.38M	-203.28M	-102.25M

Key Statistics

Valuation

Market Cap (USD)450.61B

Market Cap (Local)450.61B

P/E (TTM)71.87

P/S (TTM)7.00

MC/EBITDA23.13

Volume & Shares

Last Volume4.40M

Avg Vol (10D)4.21M

Avg Vol (30D)4.27M

Avg Vol (90D)6.27M

Shares Outstanding1.77B

Growth Indicators

Revenue TTM/Ann1.05

Net Income TTM/Ann1.48

EBITDA TTM/Ann1.11

Gross Profit TTM/Ann1.07

Operating Inc TTM/Ann1.09

Currency & Exchange

Trading CurrencyUSD

Financial CurrencyUSD

Trading/USD Rate1.00

Financial/USD Rate1.00

ExchangeNYSE

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis Rinvoq to treat inflammatory diseases Imbruvica for the treatment of adult patients with blood cancers Venclexta/Venclyxto to treat blood cancers Elahere to treat various cancer and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products botox therapeutic to treat neurologic diseases Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder Duopa and Duodopa to treat Parkinson's disease Ubrelvy to treat migraine and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension Restasis to increase tear production and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection Creon, a pancreatic enzyme therapy and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.